• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Candel Therapeutics

    Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC)
    From Candel Therapeutics
    Via GlobeNewswire
    Tickers CADL
    Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting
    From Candel Therapeutics
    Via GlobeNewswire
    Tickers CADL
    Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
    From Candel Therapeutics
    Via GlobeNewswire
    Tickers CADL
    Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
    From Candel Therapeutics
    Via GlobeNewswire
    Tickers CADL
    Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
    From Candel Therapeutics
    Via GlobeNewswire
    Tickers CADL
    Candel Therapeutics to Join Russell 3000® Index
    From Candel Therapeutics
    Via GlobeNewswire
    Tickers CADL
    FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma
    From Candel Therapeutics
    Via GlobeNewswire
    Tickers CADL
    Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting
    From Candel Therapeutics
    Via GlobeNewswire
    Tickers CADL
    Candel Therapeutics to Present at the Jefferies Global Healthcare Conference
    From Candel Therapeutics
    Via GlobeNewswire
    Tickers CADL
    Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting
    From Candel Therapeutics
    Via GlobeNewswire
    Tickers CADL
    Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
    From Candel Therapeutics
    Via GlobeNewswire
    Tickers CADL
    Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
    From Candel Therapeutics
    Via GlobeNewswire
    Tickers CADL
    Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
    From Candel Therapeutics
    Via GlobeNewswire
    Tickers CADL
    Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
    From Candel Therapeutics
    Via GlobeNewswire
    Tickers CADL
    Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
    From Candel Therapeutics
    Via GlobeNewswire
    Tickers CADL
    Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma
    From Candel Therapeutics
    Via GlobeNewswire
    Tickers CADL
    Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights
    From Candel Therapeutics
    Via GlobeNewswire
    Tickers CADL
    Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate
    From Candel Therapeutics
    Via GlobeNewswire
    Tickers CADL
    CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma
    From Candel Therapeutics
    Via GlobeNewswire
    Tickers CADL
    Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts
    From Candel Therapeutics
    Via GlobeNewswire
    Tickers CADL
    Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer
    From Candel Therapeutics
    Via GlobeNewswire
    Tickers CADL
    Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN™ Discovery Platform, and Key Clinical Readouts for CAN-2409
    From Candel Therapeutics
    Via GlobeNewswire
    Tickers CADL
    Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
    From Candel Therapeutics
    Via GlobeNewswire
    Tickers CADL
    Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC
    From Candel Therapeutics
    Via GlobeNewswire
    Tickers CADL
    Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
    From Candel Therapeutics
    Via GlobeNewswire
    Tickers CADL
    Candel Therapeutics Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110
    From Candel Therapeutics
    Via GlobeNewswire
    Tickers CADL
    Candel Therapeutics Announces Three Abstracts Accepted for Poster Presentations at SITC 2023 Annual Meeting
    From Candel Therapeutics
    Via GlobeNewswire
    Tickers CADL
    Candel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer
    From Candel Therapeutics
    Via GlobeNewswire
    Tickers CADL
    Candel Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
    From Candel Therapeutics
    Via GlobeNewswire
    Tickers CADL
    Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
    From Candel Therapeutics
    Via GlobeNewswire
    Tickers CADL
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.